Nasal Peptides Are Expanding: Delivery Straight Toward the Brain

Why nasal peptides are having a moment

Peptides are powerful but delicate. They are usually too large and too easily degraded to survive the digestive tract, which is why the default route for most peptide drugs has historically been an injection. That works, but it is inconvenient for chronic use, it requires needles and cold-chain handling, and it limits how easily a peptide can reach tissues like the brain. Against that backdrop, the nasal route has quietly become one of the most interesting delivery frontiers — and the reason is anatomical, not marketing hype.

The lining of the nasal cavity is thin, richly supplied with blood vessels, and — crucially — connected directly to the brain through cranial nerves. That gives a spray two distinct opportunities: absorption into the systemic circulation, and a more specialized "nose-to-brain" pathway that can carry molecules toward the central nervous system while partly sidestepping the blood-brain barrier. For a class of molecules that struggles to reach the brain any other way, that is a genuinely compelling proposition.

It is worth being clear up front about framing. Several of the peptides discussed here — Semax, Selank, oxytocin, and intranasal insulin or GLP-1 formulations — are studied experimentally, and on this site they are sold strictly as research-use-only (RUO) chemicals, not approved medicines. This article explains the delivery science and the research landscape, not how to use anything. For neutral educational tools, see our research library, reconstitution guide, and dosing calculator.

The nose-to-brain pathway, explained

To understand why nasal delivery is special, it helps to understand what it is competing against. The blood-brain barrier is a tightly sealed layer of cells lining the brain's blood vessels. It exists to protect the brain, and it is extraordinarily good at keeping large, water-loving molecules — including most peptides — out of the central nervous system. A peptide injected into the bloodstream may circulate perfectly well and still never reach meaningful concentrations in the brain, simply because the barrier turns it away.

The nasal cavity offers two routes that partly get around this problem. The first is the olfactory pathway: the roof of the nasal cavity contains olfactory sensory neurons whose fibers pass through the skull and connect to the olfactory bulb of the brain. Molecules can travel along and around these nerves. The second is the trigeminal pathway, involving the trigeminal nerve that innervates the nasal lining and also connects to the brainstem. Together these give a spray a physical corridor toward the central nervous system that does not depend on crossing the blood-brain barrier from the blood.

Two things are happening at once

In practice, an intranasal peptide is doing two things simultaneously: some of it is absorbed into the systemic bloodstream through the nasal mucosa (a general delivery advantage that also skips first-pass liver metabolism), and some of it may travel by the nose-to-brain routes toward the central nervous system. How much goes where depends on the molecule, the formulation, the spray device, and even where in the nasal cavity the dose is deposited. This is why nasal delivery is powerful in principle but notoriously variable in practice.

Semax and Selank: the nasal nootropic peptides

The two peptides most associated with nasal delivery in the research-peptide world are Semax and Selank. Both originated in Russian research programs, both are studied for effects on the central nervous system, and both are typically formulated as nasal sprays — precisely because their targets are in the brain and the nose offers the most direct research route to get them there.

Semax is a short peptide studied for effects related to cognition, focus, and neuroprotection in preclinical and experimental settings, with research interest in its influence on brain-derived neurotrophic factor (BDNF) signaling. Selank is a related peptide studied more for anxiolytic-type and calming effects. They are frequently discussed together because they represent two ends of a spectrum — activating versus calming — while sharing the same delivery logic. Our Semax vs Selank comparison breaks down how the two differ, and the Semax nasal spray guide covers the practical handling questions researchers ask most.

For deeper, cited profiles, see the Semax research page and the Selank research page. The broader question of how peptides like these are thought to influence the brain is covered in how nootropic peptides affect the brain. The key point for a delivery article is simple: these peptides are studied as sprays not by accident but because the nasal route is the delivery strategy that best matches a central-nervous-system target.

Intranasal oxytocin and behavioral research

If any single peptide has defined the modern nasal-delivery research literature, it is oxytocin. Oxytocin is a naturally occurring human peptide hormone involved in social bonding, trust, and related behaviors, and it has been the subject of an enormous body of experimental work studying whether intranasal administration can influence social and emotional processing. The nasal route is central to that research because oxytocin, like other peptides, does not readily cross the blood-brain barrier from the bloodstream — so a route that can reach the brain more directly is exactly what the science needs.

It is important to be measured here. Intranasal oxytocin is one of the most heavily studied peptides in behavioral neuroscience, but the literature is genuinely mixed: results vary across studies, effect sizes are often small, and there is ongoing scientific debate about how much intranasally administered oxytocin actually reaches the brain and in what quantities. That debate is itself a useful illustration of the central challenge of nasal delivery — demonstrating that a molecule has reached its intended target in meaningful amounts. See the oxytocin research profile for a fuller, cited overview.

Intranasal insulin and GLP-1: newer frontiers

Beyond the classic nootropic and behavioral peptides, two metabolic peptides have drawn growing interest in nasal-delivery research. The first is insulin. Intranasal insulin has been studied not for controlling blood sugar — that is what injected insulin does — but for its potential effects on the brain, given evidence that the central nervous system has insulin signaling and that intranasal delivery could reach it. This is an active experimental area in cognition and neurodegeneration research, and it is a clean example of using the nose-to-brain route to study a molecule's central effects rather than its systemic ones.

The second is GLP-1. GLP-1 receptor agonists such as semaglutide have transformed metabolic medicine as injectables, and there is broad research interest in alternative delivery routes for the whole class — including oral formulations and intranasal approaches. GLP-1 receptors are present in the brain, and appetite and metabolic regulation have central components, so a nose-to-brain route is a scientifically reasonable thing to investigate. It is important to be precise: intranasal GLP-1 is a research direction, not an approved nasal product. For how the class works overall, see how GLP-1 works for weight loss.

Both examples reinforce the same theme running through this article. Nasal delivery is not interesting because it is trendy; it is interesting because there are real molecules whose most valuable targets are in or near the brain, and the nose is the most direct non-invasive corridor we have toward those targets.

Advantages — and the real limits

It would be easy to read the above and conclude that nasal delivery is a solved problem waiting to replace needles. It is not. Nasal delivery has genuine, structural advantages, and it has equally genuine limitations that keep it from being a universal answer. Both deserve honest treatment.

What nasal delivery does well

• Needle-free and self-administered, which is a major convenience and adherence advantage for chronic use.
• Fast onset, because the nasal mucosa is highly vascularized and absorption can be rapid.
• Bypasses first-pass metabolism, so a molecule is not immediately degraded by the liver as it would be after oral absorption.
• A potential path toward the brain via the olfactory and trigeminal routes that other non-invasive methods do not offer.

Where nasal delivery struggles

• Small dose volume — only a limited amount of liquid can be sprayed into the nose, capping how much drug can be delivered per dose.
• Variable absorption — a head cold, congestion, mucus, or inconsistent spray technique can meaningfully change how much is absorbed.
• Short residence time — mucociliary clearance sweeps material out of the nasal cavity quickly, limiting the absorption window.
• Mucosal irritation — repeated dosing and some permeation enhancers can irritate or damage the delicate nasal lining.
• Target-reaching uncertainty — as the oxytocin debate shows, proving how much actually reaches the brain is hard.

The comparison shows why nasal is best understood as a specialist route rather than a replacement for everything. For peptides that need to reach the brain and are used chronically, nasal delivery is compelling. For a peptide that needs a large systemic dose, injection still wins. This is exactly the kind of trade-off analysis we lay out across delivery routes in the race to replace injectable peptides.

Crossover with the site's existing nasal content

Because nasal peptides are already a significant part of the research-peptide landscape, Peptide Basics has substantial existing coverage that pairs naturally with this delivery overview. If you arrived here interested in a specific product rather than the underlying science, those pages are the better starting point — and this article is best read as the connective tissue that explains why all of them exist.

• For the practical handling questions researchers ask about nasal sprays, see the Semax nasal spray guide.
• For a head-to-head on the two flagship nootropic peptides, see Semax vs Selank.
• For the mechanism-level picture of how these molecules are thought to act centrally, see how nootropic peptides affect the brain.
• For product-level context and what to look for, see our nasal spray peptides review.
• For cited, molecule-specific profiles, see Semax, Selank, and oxytocin in the research library.

Where nasal peptide delivery is heading

The research momentum behind nasal peptides is unlikely to slow, for the simple reason that the problems it addresses are not going away. As long as peptides remain hard to deliver orally and the brain remains hard to reach from the bloodstream, a route that offers a needle-free path with nose-to-brain potential will keep attracting attention. The near-term progress is likely to come less from brand-new peptides and more from better engineering: improved spray devices for consistent deposition, formulation strategies to extend residence time on the mucosa, and gentler permeation enhancers that boost absorption without irritating the nasal lining.

That said, the honest outlook is one of cautious optimism. The oxytocin literature is a reminder that reaching the brain reliably — and proving it — remains the field's hardest problem, and that enthusiasm has sometimes outrun the evidence. The most credible framing is that nasal delivery is a maturing, specialized tool that is expanding steadily rather than a breakthrough that will replace injections wholesale. For the wider delivery context, our companion pieces on the race to replace injectable peptides and long-acting peptide formulations show where nasal fits among the alternatives.